A high-throughput panel for identifying clinically relevant mutation profiles in melanoma

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 888-897

  Dutton Regester, Ken ^a   Irwin, Darryl ^b   Hunt, Priscilla ^b   Aoude, Lauren G ^a   Tembe, Varsha ^e,f   Pupo, Gulietta M ^e,f   Lanagan, Cathy ^c   Carter, Candace D ^f   O'Connor, Linda ^c   O'Rourke, Michael ^d   Scolyer, Richard A ^e,f,g   Mann, Graham J ^e,f   Schmidt, Christopher W ^c   Herington, Adrian ^a   Hayward, Nicholas K ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b Sequenom Inc Asia Pacific   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d Morris Tower ^*  (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ALLELE; ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG TARGETING; GENE; GENE FREQUENCY; GENE MUTATION; HIGH THROUGHPUT SCREENING; MEDICAL LITERATURE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PRIORITY JOURNAL; PTK2B GENE; SENSITIVITY ANALYSIS;

ALLELES; AMINO ACID SEQUENCE; CELL LINE, TUMOR; COHORT STUDIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; SKIN NEOPLASMS;

EID: 84861893379     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0676     Document Type: Article

References (50)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701. (Pubitemid 40260892)
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet 2009;374:362-5.
3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6 Suppl 1:S11-4.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
5. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6. (Pubitemid 44325897)
6. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6. (Pubitemid 351723664)
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
8. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
9. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23:190-200.
10. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
11. Emery CM, Vijayendran KG, ZipserMC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
12. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
13. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
14. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011;17:721-30.
15. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
16. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-40.
17. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
18. Yamaguchi M, Harada K, Ando N, Kawamura T, Shibagaki N, Shimada S. Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Clin Exp Dermatol 2011;36:174-7.
19. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7. (Pubitemid 38747936)
20. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997;57:4868-75. (Pubitemid 27468996)
21. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000;165:710-5. (Pubitemid 30484736)
22. Carter C, De Silva C, Synnott M, Thompson J, Stretch J, Spillane A, et al. Bio-Specimen banking: Melanoma Institute Australia. Pigment Cell Melanoma Res 2010;23:946-7.
23. Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ. Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 1999;9:10-9. (Pubitemid 29169985)
24. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-51. (Pubitemid 46328493)
25. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10 11.
26. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8. (Pubitemid 46398669)
27. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
28. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
29. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92:2032-8. (Pubitemid 40897426)
30. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003;278:42409-18. (Pubitemid 37310512)
31. Prickett TD, grawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009;41:1127-32.
32. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010;8:67.
33. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-27.
34. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28:8503.
35. Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 2011;52:7245-55
36. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6. (Pubitemid 46630793)
37. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010;23:210-5.
38. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64. (Pubitemid 46206989)
39. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9. (Pubitemid 46621810)
40. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006;131:1734-42. (Pubitemid 44958515)
41. Terada T. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int J Clin Oncol 2010;15:453-6.
42. Curtin JA, Pinkel D, Bastian BC. Absence of PDGFRA mutations in primary melanoma. J Invest Dermatol 2008;128:488-9.
43. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39:D945-50.
44. Wallander ML, Layfield LJ, Emerson LL, Mamalis N, Davis D, Tripp SR, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 2011;24:1031-5
45. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9. (Pubitemid 26013159)
46. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
47. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, et al. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem 1997;272:18869-74. (Pubitemid 27318237)
48. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33. (Pubitemid 32366984)
49. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortiumtrial. Invest New Drugs 2012;30:741-8.
50. Li J, Xu M, Yang Z, Li A, Dong J. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest 2010;28:350-6.